PMOS: PCOS officially renamed to polyendocrine metabolic ovarian syndrome in global consensus
PCOS has been renamed polyendocrine metabolic ovarian syndrome (PMOS) in a global consensus aimed at improving diagnosis and care for the condition affecting millions worldwide.
The name change to polyendocrine metabolic ovarian syndrome, or PMOS, was announced this week after an international, evidence-based process led by Monash University and published in The Lancet. (monash.edu)
Global research effort and rollout
A multi-year, multi-organisation initiative underpinning the change surveyed patients, clinicians and researchers before settling on the new name. The process drew on thousands of responses and a formal consensus published in a leading medical journal. (pubmed.ncbi.nlm.nih.gov)
Monash University, which coordinated the work, framed the update as a correction to terminology that over-emphasized ovarian cysts and under-recognized hormonal and metabolic features. The team says PMOS better captures the condition’s systemic nature and the range of health risks it carries. (monash.edu)
Health organisations including the Endocrine Society and major medical outlets have endorsed the change and urged a phased adoption in clinical materials and public messaging. Officials say the transition will require coordinated education for clinicians and patients over the coming years. (endocrine.org)
Diagnostic criteria and clinical definition
Under the revised framework clinicians will still use established diagnostic principles, which require two of three core features to establish a PMOS diagnosis. The criteria emphasize menstrual irregularities, signs of androgen excess, and specific ovarian or hormonal markers. (pubmed.ncbi.nlm.nih.gov)
Medical experts stress that the clinical tests and thresholds used in Canada remain the same for now, but the new name is intended to broaden clinician awareness of associated metabolic and mental-health risks. That recognition aims to prompt screening for conditions such as insulin resistance and mood disorders alongside reproductive assessment. (endocrine.org)
Practitioners will continue to exclude other causes that can mimic PMOS symptoms, including thyroid disease, elevated prolactin and pregnancy, before confirming the diagnosis. Treatment strategies—ranging from lifestyle management to medications such as combined hormonal contraceptives—are expected to remain unchanged in the short term. (pubmed.ncbi.nlm.nih.gov)
Why the term PCOS was judged misleading
Clinicians and patient advocates argued that “polycystic ovary syndrome” had become a misnomer because many people meeting diagnostic criteria do not have ovarian cysts. The older label concentrated attention on gynecological findings at the expense of metabolic and endocrine dimensions. (endocrine.org)
Changing the name aims to reduce diagnostic confusion—both among patients who mistakenly assume cysts must be present, and among providers who historically linked the condition mainly to fertility concerns. Advocates say the rebrand should make it easier for those affected to receive comprehensive care beyond reproductive issues. (apnews.com)
Perspectives from Calgary: patients and clinicians
Local patient research partners and specialists welcomed the shift as overdue. A Calgary patient-research collaborator described years of being steered toward fertility-based responses before other symptoms were taken seriously. She said the new name better reflects lived experience and could help people access care earlier.
A University of Calgary endocrinologist noted that the renaming clarifies the condition’s multi-system impact and may reduce misdiagnosis among people who have enlarged ovarian follicles but not true cysts. The physician added that broader clinician education will be essential to translate the name change into improved screening and management.
Potential effects on care, awareness and research
Experts expect the renaming to influence public-facing materials, clinical guidelines and research priorities, though the practical effect will evolve over time. Supporters say PMOS may prompt more comprehensive screening for metabolic issues such as high blood pressure, dyslipidemia and risk of Type 2 diabetes. (monash.edu)
Researchers who led the renaming process have also called for updated educational resources and funding to investigate areas historically under-examined, including mental-health outcomes and eating disorders linked to the condition. The name change is being positioned as a first step toward shifting research and care from a narrow reproductive focus to a wider endocrine and metabolic perspective. (pubmed.ncbi.nlm.nih.gov)
The international rollout will be gradual, with professional bodies and patient groups coordinating translations, clinician briefings and public information campaigns to minimize confusion during the transition. Observers say consistent use of the new terminology in clinical coding, lab reports and patient resources will be critical to its success. (monash.edu)
Public-health advocates and clinicians in Canada say they will watch how the new name affects screening practices, referral patterns and access to multidisciplinary care. Many hope the change will reduce the number of people who are dismissed or given fertility-focused advice when their needs are broader.
Health systems, guideline developers and patient organisations will need to work together to update protocols and ensure that people living with PMOS receive appropriate and timely interventions.
